[{"orgOrder":0,"company":"Apurano Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Adezunap","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Apurano Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Spray","sponsorNew":"Apurano Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apurano Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apurano Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Adezunap","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Apurano Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Spray","sponsorNew":"Apurano Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apurano Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apurano Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Adezunap","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Apurano Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Spray","sponsorNew":"Apurano Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apurano Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apurano Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Adezunap","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Apurano Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Spray","sponsorNew":"Apurano Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apurano Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apurano Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Adezunap","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Apurano Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Spray","sponsorNew":"Apurano Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apurano Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apurano Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Adezunap","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Apurano Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Spray","sponsorNew":"Apurano Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apurano Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apurano Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Adezunap","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Apurano Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Spray","sponsorNew":"Apurano Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apurano Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apurano Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Adezunap","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Apurano Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Spray","sponsorNew":"Apurano Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apurano Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astrogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AST-001","moa":"Glutamine","graph1":"Neurology","graph2":"Phase III","graph3":"Astrogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astrogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astrogen \/ Inapplicable"},{"orgOrder":0,"company":"Cutia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"Cutia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cutia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cutia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RDC Clinical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RDC Clinical \/ Inapplicable"},{"orgOrder":0,"company":"Invex Therapeutics","sponsor":"Premier Research Group | University Hospital Birmingham | University of Iowa","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Invex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Invex Therapeutics \/ Premier Research Group | University Hospital Birmingham | University of Iowa","highestDevelopmentStatusID":"10","companyTruncated":"Invex Therapeutics \/ Premier Research Group | University Hospital Birmingham | University of Iowa"},{"orgOrder":0,"company":"Laboratorios SILANES","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MEXICO","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Voltage-gated calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Laboratorios SILANES","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Laboratorios SILANES \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios SILANES \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios SILANES","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MEXICO","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexketoprofen Trometamol","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Laboratorios SILANES","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Laboratorios SILANES \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios SILANES \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios SILANES","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MEXICO","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Laboratorios SILANES","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laboratorios SILANES \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios SILANES \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios SILANES","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MEXICO","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etoricoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Laboratorios SILANES","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Laboratorios SILANES \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios SILANES \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios SILANES","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MEXICO","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etoricoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Laboratorios SILANES","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios SILANES \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios SILANES \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios SILANES","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MEXICO","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Etoricoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Laboratorios SILANES","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Laboratorios SILANES \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios SILANES \/ Inapplicable"},{"orgOrder":0,"company":"Sinotau Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XTR006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Sinotau Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sinotau Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinotau Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Xiromed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Xiromed"},{"orgOrder":0,"company":"Xiromed","sponsor":"IntelGenx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Xiromed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Xiromed \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"Xiromed \/ IntelGenx"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"Vanilloid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Semnur Pharmaceuticals","sponsor":"Denali Capital Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Merger","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Semnur Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Semnur Pharmaceuticals \/ Denali Capital Acquisition Corp","highestDevelopmentStatusID":"10","companyTruncated":"Semnur Pharmaceuticals \/ Denali Capital Acquisition Corp"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cali Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"Cali Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Cali Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cali Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"Vanilloid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arthritis Innovation Corporation","sponsor":"Allucent","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"F14","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Arthritis Innovation Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-articular","sponsorNew":"Arthritis Innovation Corporation \/ Allucent","highestDevelopmentStatusID":"10","companyTruncated":"Arthritis Innovation Corporation \/ Allucent"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Celecoxib","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||estrogens","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Grunenthal"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||estrogens","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||estrogens","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||estrogens","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Spine BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Viscogliosi Bros.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intradiscal Injection","sponsorNew":"Spine BioPharma \/ Viscogliosi Bros.","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioPharma \/ Viscogliosi Bros."},{"orgOrder":0,"company":"Helixmith","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Engensis","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Helixmith \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Helixmith \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Methylcobalamin","moa":"Methionine synthase","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Methylcobalamin","moa":"Methionine synthase","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Methylcobalamin","moa":"Methionine synthase","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Debamestrocel","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Debamestrocel","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Abbhi Investments","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Autologous MSC-NTF Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Abbhi Investments","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Abbhi Investments"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Autologous MSC-NTF Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Zorevunersen","moa":"TTR mRNA","graph1":"Neurology","graph2":"Phase III","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1 mRNA","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ION363","moa":"RNA-binding protein FUS messenger RNA (FUS mRNA)","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION363","moa":"RNA-binding protein FUS messenger RNA (FUS mRNA)","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AL001","moa":"monoclonal antibodies: neural","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"GUERBET","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GUERBET \/ Bracco","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Bracco"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Neurology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CinnaGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Remternetug","moa":"Amyloid","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Frexalimab","moa":"TNFSF5","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Frexalimab","moa":"TNFSF5","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Riliprubart","moa":"C1S","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | Eisai Inc","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | Eisai Inc"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Empasiprubart","moa":"C2","graph1":"Neurology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Empasiprubart","moa":"C2","graph1":"Neurology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Neurology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Banner Alzheimer's Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Banner Alzheimer's Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Banner Alzheimer's Institute \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Banner Alzheimer's Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"||Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Quanterix","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Quanterix \/ Eli Lilly"},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Quanterix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Quanterix \/ Eli Lilly"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai Inc \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Biogen"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Frontage Laboratories, Inc \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Frontage Laboratories, Inc \/ Eisai"},{"orgOrder":0,"company":"Genentech","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ AC Immune","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ AC Immune"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Termination","leadProduct":"Crenezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0.41999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.41999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ AC Immune","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ AC Immune"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Banner Alzheimer\u2019s Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Banner Alzheimer\u2019s Institute","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Banner Alzheimer\u2019s Institute"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Normal Human Immunoglobulin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":2.2000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Alector","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Alector","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Frexalimab","moa":"TNFSF5","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Frexalimab","moa":"TNFSF5","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"ImmuNext Inc","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Frexalimab","moa":"TNFSF5","graph1":"Neurology","graph2":"Phase III","graph3":"ImmuNext Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmuNext Inc \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"ImmuNext Inc \/ Royalty Pharma"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Amlenetug","moa":"SNCA","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Amlenetug","moa":"SNCA","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amlenetug","moa":"SNCA","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Riliprubart","moa":"C1S","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"POLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Neurology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polpharma Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Demerger","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Neurology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"POLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Neurology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polpharma Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"POLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Neurology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polpharma Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Neurology","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"NEMA Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Phenobarbital Sodium","moa":"GABR","graph1":"Neurology","graph2":"Phase III","graph3":"NEMA Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NEMA Research \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NEMA Research \/ Inapplicable"},{"orgOrder":0,"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Phenobarbital Sodium","moa":"GABR","graph1":"Neurology","graph2":"Phase III","graph3":"SPARC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SPARC \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"SPARC \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Polysan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"RUSSIA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Neurology","graph2":"Phase III","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Polysan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polysan \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Immedica Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Immedica Pharma"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Agreement","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Immedica Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Immedica Pharma"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Public Offering","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Felbinac Trometamol","moa":"COXs","graph1":"Neurology","graph2":"Phase III","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hamilton Health Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Felbinac Trometamol","moa":"COXs","graph1":"Neurology","graph2":"Phase III","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GTX-104","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSPC ZhongQi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSPC ZhongQi \/ Inapplicable"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Yangtze River Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Yangtze River Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neumentum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neumentum \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neumentum \/ Inapplicable"},{"orgOrder":0,"company":"Neumentum","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Neumentum","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Neumentum \/ Nuance Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Neumentum \/ Nuance Pharma"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Neumentum","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nuance Pharma \/ Neumentum","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pharma \/ Neumentum"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Nantahala Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Nantahala Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Nantahala Capital Management"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"APRINOIA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"18-F APN-1607","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"APRINOIA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"APRINOIA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"APRINOIA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"18-F PI-2620","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Life Molecular Imaging \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Life Molecular Imaging \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CT-P53","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Gadoquatrane","moa":"Gadolinium (MRI contrast)","graph1":"Neurology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Gadoquatrane","moa":"Gadolinium (MRI contrast)","graph1":"Neurology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CYB704","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Vitruvias Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Vitruvias Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Vitruvias Therapeutics"},{"orgOrder":0,"company":"PharmaTher","sponsor":"CC Biotechnology Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaTher \/ CC Biotechnology Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ CC Biotechnology Corporation"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Frexalimab","moa":"TNFSF5","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amlenetug","moa":"SNCA","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"PrimeStreet Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ PrimeStreet Capital","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ PrimeStreet Capital"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Gadoquatrane","moa":"Gadolinium (MRI contrast)","graph1":"Neurology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Gesval S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Gesval S.A","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Gesval S.A"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Neurology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Grace Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Acasti Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Acasti Pharma"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Alcami","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Alcami","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Alcami"},{"orgOrder":0,"company":"PAION UK LTD","sponsor":"University Medical Center Groningen | QPS Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"PAION UK LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PAION UK LTD \/ University Medical Center Groningen | QPS Holdings","highestDevelopmentStatusID":"10","companyTruncated":"PAION UK LTD \/ University Medical Center Groningen | QPS Holdings"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GTX-104","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"TSRL","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ TSRL","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ TSRL"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Formosa Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Steroid","year":"2021","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sosei Heptares","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sosei Heptares \/ Formosa Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Heptares \/ Formosa Laboratories"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"William Blair","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ William Blair","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ William Blair"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"American Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AG-920","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"American Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"American Genomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"American Genomics \/ Inapplicable"},{"orgOrder":0,"company":"American Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AG-920","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"American Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"American Genomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"American Genomics \/ Inapplicable"},{"orgOrder":0,"company":"American Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AG-920","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"American Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"American Genomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"American Genomics \/ Inapplicable"},{"orgOrder":0,"company":"American Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AG-920","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"American Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"American Genomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"American Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor; anion channel | Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SK Life Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SK Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AMX0035","moa":"Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor | Stem cell growth factor receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AMX0035","moa":"Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MT-1186","moa":"TDP-43","graph1":"Neurology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mitsubishi Tanabe Pharma America \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma America \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MT-1186","moa":"TDP-43","graph1":"Neurology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mitsubishi Tanabe Pharma America \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma America \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HSK16149","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MT-1186","moa":"TDP-43","graph1":"Neurology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mitsubishi Tanabe Pharma America \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma America \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRG2010","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AVP-786","moa":"Opioid receptor sigma 1 (OPRS1)","graph1":"Neurology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AVP-786","moa":"Opioid receptor sigma 1 (OPRS1)","graph1":"Neurology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Neurology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Neurology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Neurology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ACP-204","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Neurology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Carisbamate","moa":"tranquilizers\/antiepileptics (propanediol and pentanediol groups)","graph1":"Neurology","graph2":"Phase III","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"SK Life Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SK Life Science \/ Inapplicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Carisbamate","moa":"tranquilizers\/antiepileptics (propanediol and pentanediol groups)","graph1":"Neurology","graph2":"Phase III","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"SK Life Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SK Life Science \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"Serotonin 2c (5-HT2c) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eisai Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Neurology","graph2":"Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.23000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.23000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.23000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ EMD Serono","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ EMD Serono"},{"orgOrder":0,"company":"Merck Group","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ EMD Serono","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ EMD Serono"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ National Institute on Aging"},{"orgOrder":0,"company":"Biogen","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biogen \/ Denali Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Denali Therapeutics"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"Dopamine D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ EMD Serono","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ EMD Serono"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biogen \/ Denali Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Denali Therapeutics"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"Dopamine D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"Dopamine D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"Dopamine D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Apsen Farmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Apsctc","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Apsen Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Apsen Farmaceutica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apsen Farmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"XEN496","moa":"KCNQ potassium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"XEN496","moa":"KCNQ potassium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Alprazolam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Alprazolam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Voltage-gated calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor; anion channel | Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"PF614","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medlab Clinical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Medlab Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Medlab Clinical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medlab Clinical \/ Inapplicable"},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Alprazolam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.27000000000000002,"dosageForm":"Oral Inhalation","sponsorNew":"Engage Therapeutics \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Engage Therapeutics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Public Offering","leadProduct":"Ezogabine","moa":"KCNQ (Kv7) potassium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Jefferies"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ananda Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Ananda Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ananda Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ananda Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Ensysce Biosciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Ensysce Biosciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Prolonged Release","sponsorNew":"Neurim Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurim Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"RUSSIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MMH-MAP","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Materia Medica Holding \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rizatriptan Benzoate","moa":"Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Neurology","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Epygenix","sponsor":"Harmony Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clemizole hydrochloride","moa":"TRPC5","graph1":"Neurology","graph2":"Phase III","graph3":"Epygenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix \/ Harmony Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Epygenix \/ Harmony Biosciences"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NE3107","moa":"Estrogen receptor (ESR)","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"Allergan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atogepant","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Allergan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Inapplicable"},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Neurology","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Soticlestat","moa":"Cholesterol 24-hydroxylase","graph1":"Neurology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal troponin complex","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Codeine","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IMU-838","moa":"Dihydroorotate dehydrogenase","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Soticlestat","moa":"Cholesterol 24-hydroxylase","graph1":"Neurology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMU-838","moa":"Dihydroorotate dehydrogenase","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"Synaptic vesicular amine transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ TFS Trial Form Support","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal troponin complex","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylbenzylamine","moa":"Phosphodiesterase 5 (PDE5)","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Zogenix","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"University Health Network, Toronto \/ Zogenix","highestDevelopmentStatusID":"10","companyTruncated":"University Health Network, Toronto \/ Zogenix"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Theravance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Canadian Institutes of Health Research | Physician Services Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Neurology","graph2":"Phase III","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Unity Health Toronto \/ Canadian Institutes of Health Research | Physician Services Incorporated","highestDevelopmentStatusID":"10","companyTruncated":"Unity Health Toronto \/ Canadian Institutes of Health Research | Physician Services Incorporated"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Cerecin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tricaprylin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Cerecin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerecin \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerecin \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levetiracetam","moa":"Voltage-gated N-type calcium channel alpha-1B subunit | Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hamilton Health Sciences \/ McMaster University","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ McMaster University"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tianjin Tasly Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenfluramine","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MR-107A-02","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MR-107A-02","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Soticlestat","moa":"Cholesterol 24-hydroxylase","graph1":"Neurology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Odense University Hospital","sponsor":"University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Odense University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Odense University Hospital \/ University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","highestDevelopmentStatusID":"10","companyTruncated":"Odense University Hospital \/ University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Solengepras","moa":"G-protein coupled receptor 6 (GPR6)","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"SCN10A","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"SCN10A","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Prevail Infoworks","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Prevail Infoworks","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Prevail Infoworks"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"NICHD Global Network for Women's and Children's Health","sponsor":"KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College, Belagavi, India | Gates Foundation | University of Virginia | University of Alabama at Birmingham | Thomas Jefferson University | Columbia University | University of Colorado,","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Caffeine Citrate","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"NICHD Global Network for Women's and Children's Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"NICHD Global Network for Women's and Children's Health \/ KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College, Belagavi, India | Gates Foundation | University of Virginia | University of Alabama at Birmingham | Thomas Jefferson University | Columbia University | University of Colorado,","highestDevelopmentStatusID":"10","companyTruncated":"NICHD Global Network for Women's and Children's Health \/ KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College, Belagavi, India | Gates Foundation | University of Virginia | University of Alabama at Birmingham | Thomas Jefferson University | Columbia University | University of Colorado,"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Neurology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celgene Corporation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Safinamide Methanesulfonate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Newron Pharmaceuticals \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ Zambon Group SpA"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"Synaptic vesicular amine transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Celecoxib","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"10","companyTruncated":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ BioVie"},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ BioVie"},{"orgOrder":0,"company":"NeurMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"Roskamp Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nilvadipine","moa":"Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Roskamp Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Roskamp Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Roskamp Institute \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Denovo Biopharma"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AriBio","sponsor":"Adaptive Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5 inhibitors","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Adaptive Research","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Adaptive Research"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5 inhibitors","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5 inhibitors","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5 inhibitors","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5 inhibitors","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5 inhibitors","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Mirodenafil","moa":"PDE5 inhibitors","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0.77000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.77000000000000002,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Alerce Medical Technology Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series E Financing","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Alerce Medical Technology Partners","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Alerce Medical Technology Partners"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ National Institute on Aging"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series D Financing","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"B. Dyson Capital Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.13,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ B. Dyson Capital Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ B. Dyson Capital Advisors"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institute on Aging"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Neurology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Neurology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Orphazyme","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Phase III","graph3":"CytRx Corporation","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"Oral Capsule","sponsorNew":"CytRx Corporation \/ Orphazyme","highestDevelopmentStatusID":"10","companyTruncated":"CytRx Corporation \/ Orphazyme"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Troponin, cardiac muscle | Phosphodiesterase 3","graph1":"Neurology","graph2":"Phase III","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orion Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orion Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Treeway","sponsor":"Specialised Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Treeway","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Treeway \/ Specialised Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Treeway \/ Specialised Therapeutics"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Ferrer Internacional \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Inapplicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Ferrer Internacional \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Inapplicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Ferrer Internacional \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Inapplicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Treeway","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Ferrer Internacional \/ Treeway","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Treeway"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal troponin complex","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal troponin complex","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal troponin complex","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"The ALS Association","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tirasemtiv","moa":"Fast skeletal troponin complex","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ The ALS Association","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ The ALS Association"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"Canadian Cancer Society","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Neurology","graph2":"Phase III","graph3":"Canadian Cancer Society","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Canadian Cancer Society \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"10","companyTruncated":"Canadian Cancer Society \/ Canadian Institutes of Health Research"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iclepertin","moa":"SLC6A9","graph1":"Neurology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Padsevonil","moa":"GABA-A receptor; anion channel | Synaptic vesicle protein","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"Serotonin 2c (5-HT2c) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Tenacia Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.28000000000000003,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Tenacia Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Tenacia Biotechnology"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"SCN10A","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rofecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tremeau Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rofecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tremeau Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MedDay Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Biotin","moa":"Krebs cycle activatior","graph1":"Neurology","graph2":"Phase III","graph3":"MedDay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MedDay Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MedDay Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Merck & Co"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Merck & Co"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Osmotica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Osmotica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Principia Biopharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Principia Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Principia Biopharma \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Principia Biopharma \/ Sanofi"},{"orgOrder":0,"company":"Principia Biopharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Principia Biopharma","amount2":3.6800000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":3.6800000000000002,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Principia Biopharma \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Principia Biopharma \/ Sanofi"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.23999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.089999999999999997,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ SVB Leerink"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Koneksa","sponsor":"old Sano","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Koneksa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Koneksa \/ old Sano","highestDevelopmentStatusID":"10","companyTruncated":"Koneksa \/ old Sano"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"old Sano","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Terran Biosciences \/ old Sano","highestDevelopmentStatusID":"10","companyTruncated":"Terran Biosciences \/ old Sano"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocodone Bitartrate","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Hepion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharma Two B \/ Hepion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Hepion Pharmaceuticals"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Hepion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharma Two B \/ Hepion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Hepion Pharmaceuticals"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharma Two B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Inapplicable"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharma Two B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Inapplicable"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharma Two B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Inapplicable"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Pharma Two B \/ Myung In Pharm","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Myung In Pharm"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Posiphen tartrate","moa":"TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ TFS Trial Form Support","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Solengepras","moa":"GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":8.6999999999999993,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":8.6999999999999993,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.34999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"NovaQuest Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.13,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ NovaQuest Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ NovaQuest Capital Management"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.34999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ J.P. Morgan"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.34999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ J.P. Morgan"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.34999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ J.P. Morgan"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Glutamine","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ponesimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Neurology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.070000000000000007,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"RUSSIA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Prospekta","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Materia Medica Holding \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Hyundai Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BPDO-1603","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Hyundai Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hyundai Pharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hyundai Pharm \/ Inapplicable"},{"orgOrder":0,"company":"EMS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Praga","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Inapplicable"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"NPC-09","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nobelpharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nobelpharma \/ Inapplicable"},{"orgOrder":0,"company":"Vertanical GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"VER-01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Vertanical GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vertanical GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertanical GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tianjin Tasly Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Acetyllevocarnitine HCl","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Semmelweis University","sponsor":"National Research Development Fund, Hungary | Meditop Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Tolperisone","moa":"deuterated compounds","graph1":"Neurology","graph2":"Phase III","graph3":"Semmelweis University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Semmelweis University \/ National Research Development Fund, Hungary | Meditop Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Semmelweis University \/ National Research Development Fund, Hungary | Meditop Pharmaceutical"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSK16149","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"EMS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DIT112","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HSK16149","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"N0750","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"AVANIR PHARMS","sponsor":"Otsuka America Pharmaceutical, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Deudextromethorphan HBr","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"AVANIR PHARMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AVANIR PHARMS \/ Otsuka America Pharmaceutical, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"AVANIR PHARMS \/ Otsuka America Pharmaceutical, Inc."},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deudextromethorphan HBr","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Otsuka Holdings \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deudextromethorphan HBr","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Tottenham Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Merger","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.54000000000000004,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.54000000000000004,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Tottenham Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Tottenham Acquisition"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AMX0035","moa":"Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ACP-204","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ACP-204","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Leriglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Neurology","graph2":"Phase III","graph3":"Minoryx Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Minoryx Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Neurology","graph2":"Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Neurology","graph2":"Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Sperogenix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Leriglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Neurology","graph2":"Phase III","graph3":"Minoryx Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Sperogenix Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Minoryx Therapeutics \/ Sperogenix Therapeutics"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Canaccord Genuity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Canaccord Genuity"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Canaccord Genuity"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ George Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ George Clinical"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Maryland Board of Public Works","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Maryland Board of Public Works","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Maryland Board of Public Works"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Funding","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ National Institutes of Health"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Symbiosis II, LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Series D Financing","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Symbiosis II, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Symbiosis II, LLC"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Tottenham Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Merger","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.54000000000000004,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Tottenham Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Tottenham Acquisition"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRG2010","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Neurology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Neurology","graph2":"Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Neurology","graph2":"Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biogen \/ Denali Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Denali Therapeutics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Alprazolam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Engage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Engage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ezogabine","moa":"KCNQ (Kv7) potassium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institute on Aging"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IMU-838","moa":"Dihydroorotate dehydrogenase","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MR-107A-02","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Solengepras","moa":"G-protein coupled receptor 6 (GPR6)","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ National Institutes of Health"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"AriBio","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5 inhibitors","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Cleveland Clinic","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Cleveland Clinic"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5 inhibitors","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5 inhibitors","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ SK Chemicals","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ SK Chemicals"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Reldesemtiv","moa":"Fast skeletal troponin complex","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Astellas Pharma"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal troponin complex","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"SCN10A","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.23999999999999999,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.23999999999999999,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.23999999999999999,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Evercore ISI"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Evercore ISI"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Soticlestat","moa":"Cholesterol 24-hydroxylase","graph1":"Neurology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Ovid Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Ovid Therapeutics"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Cerevance","sponsor":"Agent Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Solengepras","moa":"GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Agent Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Agent Capital"},{"orgOrder":0,"company":"Cerevance","sponsor":"Gates Frontier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Solengepras","moa":"GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Gates Frontier","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Gates Frontier"},{"orgOrder":0,"company":"Cerevance","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Solengepras","moa":"GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Google Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Google Ventures"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Solengepras","moa":"GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Solengepras","moa":"GPR6","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSK16149","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AMX0035","moa":"Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor; anion channel | Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SK Life Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SK Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSK16149","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Quotient Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Quotient Sciences"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Padsevonil","moa":"GABA-A receptor; anion channel | Synaptic vesicle protein","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tavapadon","moa":"Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AMX0035","moa":"Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"Serotonin 2c (5-HT2c) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eisai Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Siponimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Neurology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocodone Bitartrate","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Percutaneous Liquid","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"dopamine receptor agonists; phosphoro-derivatives","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"dopamine receptor agonists; phosphoro-derivatives","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"dopamine receptor agonists; phosphoro-derivatives","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TEV-48125","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Phase III","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Brigham and Women's Hospital \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Brigham and Women's Hospital \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Remternetug","moa":"Amyloid","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Riliprubart","moa":"C1S","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Neurology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MorphoSys \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tanezumab","moa":"Beta-nerve growth factor","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Eli Lilly"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"The Canadian Pain Society | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"University Health Network, Toronto \/ The Canadian Pain Society | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"University Health Network, Toronto \/ The Canadian Pain Society | Pfizer Inc"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":3.5899999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":3.5899999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":3.5899999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":3.5899999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Mapi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"polymers","graph1":"Neurology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Mapi Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Mapi Pharma"},{"orgOrder":0,"company":"NeuroDerm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"NeuroDerm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"NeuroDerm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NeuroDerm \/ Inapplicable"},{"orgOrder":0,"company":"NeuroDerm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"NeuroDerm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"NeuroDerm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NeuroDerm \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"NeuroDerm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ NeuroDerm","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ NeuroDerm"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Peginterferon Beta-1a","moa":"Interferon alpha\/beta receptor","graph1":"Neurology","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CinnaGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.16,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.16,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"MET","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"dopamine receptor agonists; phosphoro-derivatives","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Series B Financing","leadProduct":"Midazolam","moa":"||GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repurposed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Neurology","graph2":"Phase III","graph3":"Repurposed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Repurposed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Repurposed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Daehwa Pharmaceutical Co. Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"Cholinesterases; ACHE & BCHE","graph1":"Neurology","graph2":"Phase III","graph3":"Daehwa Pharmaceutical Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Daehwa Pharmaceutical Co. Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daehwa Pharmaceutical Co. Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"Cholinesterases; ACHE & BCHE","graph1":"Neurology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Towa Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Biocad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"RUSSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BCD-132","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0.55000000000000004,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.55000000000000004,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Rimabotulinumtoxin B","moa":"SNAP25","graph1":"Neurology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSK21542","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HSK21542","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Alzheimer's Clinical Trials Consortium | Biogen | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai Inc \/ Alzheimer's Clinical Trials Consortium | Biogen | National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Alzheimer's Clinical Trials Consortium | Biogen | National Institute on Aging"},{"orgOrder":0,"company":"Alector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alector \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Riliprubart","moa":"C1S","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"George Medvedev","sponsor":"H. Lundbeck AS | Surrey Neuroplasticity Clinic | Royal Columbian Hospital | Surrey Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Phase III","graph3":"George Medvedev","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"George Medvedev \/ H. Lundbeck AS | Surrey Neuroplasticity Clinic | Royal Columbian Hospital | Surrey Memorial Hospital","highestDevelopmentStatusID":"10","companyTruncated":"George Medvedev \/ H. Lundbeck AS | Surrey Neuroplasticity Clinic | Royal Columbian Hospital | Surrey Memorial Hospital"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lu AF82422","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1S","graph1":"Neurology","graph2":"Phase III","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dianthus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dianthus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Alzamend Neuro","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Neurology","graph2":"Phase III","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altasciences Company Inc \/ Alzamend Neuro","highestDevelopmentStatusID":"10","companyTruncated":"Altasciences Company Inc \/ Alzamend Neuro"},{"orgOrder":0,"company":"Helixmith","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Engensis","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helixmith \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Helixmith \/ Inapplicable"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Alzheimer's Drug Discovery Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Nabilone","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Alzheimer's Drug Discovery Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Alzheimer's Drug Discovery Foundation"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Nabiximols","moa":"cannabinol derivatives","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Nabiximols","moa":"cannabinol derivatives","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yangtze River Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Yangtze River Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Aculys Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aculys Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aculys Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"National Cancer Center Hospital East","sponsor":"AstraZeneca | Japan Agency for Medical Research and Development | Japan Clinical Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Neurology","graph2":"Phase III","graph3":"National Cancer Center Hospital East","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Center Hospital East \/ AstraZeneca | Japan Agency for Medical Research and Development | Japan Clinical Oncology Group","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Center Hospital East \/ AstraZeneca | Japan Agency for Medical Research and Development | Japan Clinical Oncology Group"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation | Laboratory of excellence DISTALZ | R\u00e9gion Nord-Pas de Calais, France | Meo coffee","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University Hospital, Lille \/ Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation | Laboratory of excellence DISTALZ | R\u00e9gion Nord-Pas de Calais, France | Meo coffee","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Lille \/ Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation | Laboratory of excellence DISTALZ | R\u00e9gion Nord-Pas de Calais, France | Meo coffee"},{"orgOrder":0,"company":"Alzheimer's Prevention and Reversal Project, Inc.","sponsor":"Four Winds Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Precision Medicine Approach","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheimer's Prevention and Reversal Project, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alzheimer's Prevention and Reversal Project, Inc. \/ Four Winds Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Alzheimer's Prevention and Reversal Project, Inc. \/ Four Winds Foundation"},{"orgOrder":0,"company":"Amzell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"AMZ002","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Amzell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Amzell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amzell \/ Inapplicable"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Rovatirelin","moa":"Thyrotropin-releasing hormone receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ION363","moa":"RNA-binding protein FUS messenger RNA (FUS mRNA)","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kedrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kedrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"University of Milan","sponsor":"Azienda Farmaceutica Italiana","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Polaprezinc","moa":"Tumor necrosis factor; Interleukin-6; Interleukin-3; Vascular endothelial growth factor receptor 1; Beta-nerve growth factor; Platelet-derived growth factor receptor beta; Heat shock protein HSP 90-alpha; Heat shock protein HSP 90-beta","graph1":"Neurology","graph2":"Phase III","graph3":"University of Milan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"University of Milan \/ Azienda Farmaceutica Italiana","highestDevelopmentStatusID":"10","companyTruncated":"University of Milan \/ Azienda Farmaceutica Italiana"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin-gene-related peptide receptor, CALCRL\/RAMP1","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Liquid","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Unither Pharmaceuticals","sponsor":"Excelya","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Neurology","graph2":"Phase III","graph3":"Unither Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unither Pharmaceuticals \/ Excelya","highestDevelopmentStatusID":"10","companyTruncated":"Unither Pharmaceuticals \/ Excelya"},{"orgOrder":0,"company":"Unither Pharmaceuticals","sponsor":"Aixial Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Unither Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Solution","sponsorNew":"Unither Pharmaceuticals \/ Aixial Group","highestDevelopmentStatusID":"10","companyTruncated":"Unither Pharmaceuticals \/ Aixial Group"},{"orgOrder":0,"company":"Brazilian Clinical Research Institute","sponsor":"Brainfarma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metamizole","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Brazilian Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brazilian Clinical Research Institute \/ Brainfarma","highestDevelopmentStatusID":"10","companyTruncated":"Brazilian Clinical Research Institute \/ Brainfarma"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxymorphone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HSK3486","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Allergan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atogepant","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Allergan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Inapplicable"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"Pfizer Inc | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vanderbilt University Medical Center \/ Pfizer Inc | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"10","companyTruncated":"Vanderbilt University Medical Center \/ Pfizer Inc | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Peking Union Medical College Hospital \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Repurposed Therapeutics","sponsor":"Defender Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DPI-386","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Repurposed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Repurposed Therapeutics \/ Defender Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Repurposed Therapeutics \/ Defender Pharmaceuticals"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Averitas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cassava Sciences \/ Premier Research Group","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Premier Research Group"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin-A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cassava Sciences \/ Premier Research Group","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Premier Research Group"},{"orgOrder":0,"company":"Arafarma","sponsor":"Fundaci\u00f3n Te\u00f3filo Hernando","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Arafarma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arafarma \/ Fundaci\u00f3n Te\u00f3filo Hernando","highestDevelopmentStatusID":"10","companyTruncated":"Arafarma \/ Fundaci\u00f3n Te\u00f3filo Hernando"},{"orgOrder":0,"company":"University of Florida","sponsor":"National Institute of Neurological Disorders and Stroke | University of Cincinnati | Medical University of South Carolina | Johnson & Johnson Innovative Medicine | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Neurology","graph2":"Phase III","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ National Institute of Neurological Disorders and Stroke | University of Cincinnati | Medical University of South Carolina | Johnson & Johnson Innovative Medicine | AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"University of Florida \/ National Institute of Neurological Disorders and Stroke | University of Cincinnati | Medical University of South Carolina | Johnson & Johnson Innovative Medicine | AstraZeneca"},{"orgOrder":0,"company":"University Hospital, Bonn","sponsor":"German Federal Ministry of Education and Research | Pharmacy of the University Hospital Leipzig | nextevidence","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"University Hospital, Bonn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Bonn \/ German Federal Ministry of Education and Research | Pharmacy of the University Hospital Leipzig | nextevidence","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Bonn \/ German Federal Ministry of Education and Research | Pharmacy of the University Hospital Leipzig | nextevidence"},{"orgOrder":0,"company":"KeifeRx, LLC","sponsor":"Worldwide Clinical Trials | Life Molecular Imaging | Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Neurology","graph2":"Phase III","graph3":"KeifeRx, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KeifeRx, LLC \/ Worldwide Clinical Trials | Life Molecular Imaging | Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"KeifeRx, LLC \/ Worldwide Clinical Trials | Life Molecular Imaging | Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Mercy Health","sponsor":"Lake Erie College of Osteopathic Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Droperidol","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mercy Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercy Health \/ Lake Erie College of Osteopathic Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Mercy Health \/ Lake Erie College of Osteopathic Medicine"},{"orgOrder":0,"company":"NEMA Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"NEMA Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NEMA Research \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NEMA Research \/ Inapplicable"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leiden University Medical Center \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Leiden University Medical Center \/ ZonMw"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HSK3486","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Second Affiliated Hospital, Zhejiang University","sponsor":"Credit Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tizanidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"Second Affiliated Hospital, Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Zhejiang University \/ Credit Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Second Affiliated Hospital, Zhejiang University \/ Credit Pharmaceutical"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HSK3486","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Repurposed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DPI-386","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Repurposed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Repurposed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Repurposed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor | Stem cell growth factor receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Sollis Therapeutics, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"Sollis Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sollis Therapeutics, Inc. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sollis Therapeutics, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"PROCTER AND GAMBLE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vitamin B1","moa":"Bacterial Pyruvate decarboxylase (Bact aceE)","graph1":"Neurology","graph2":"Phase III","graph3":"PROCTER AND GAMBLE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"PROCTER AND GAMBLE \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PROCTER AND GAMBLE \/ Inapplicable"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ McMaster University","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ McMaster University"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Institut Cancerologie de l'Ouest","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Institut Cancerologie de l'Ouest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Institut Cancerologie de l'Ouest \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Institut Cancerologie de l'Ouest \/ Grunenthal"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin-gene-related peptide receptor, CALCRL\/RAMP1","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin-gene-related peptide receptor, CALCRL\/RAMP1","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"KAZM Pharmaceuticals","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketoprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"KAZM Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KAZM Pharmaceuticals \/ McMaster University","highestDevelopmentStatusID":"10","companyTruncated":"KAZM Pharmaceuticals \/ McMaster University"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase III","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Critical Illness, Brain Dysfunction, and Survivorship Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Isoflurane","moa":"Glycine receptor (alpha-1\/beta) | Potassium channel subfamily K member 18 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 2 | GABA-A receptor; anion channel | Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10","graph1":"Neurology","graph2":"Phase III","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sedana Medical \/ Critical Illness, Brain Dysfunction, and Survivorship Center","highestDevelopmentStatusID":"10","companyTruncated":"Sedana Medical \/ Critical Illness, Brain Dysfunction, and Survivorship Center"},{"orgOrder":0,"company":"Pharmasoft","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Emoxypine Succinate","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Pharmasoft","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharmasoft \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmasoft \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Averitas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Averitas Pharma \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Grunenthal"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bioshin","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Bioshin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Disintegrating","sponsorNew":"Bioshin \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bioshin \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Gylden Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Zolmitriptan","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eversana","sponsor":"Zosano Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Zolmitriptan","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Eversana \/ Zosano Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eversana \/ Zosano Pharma"},{"orgOrder":0,"company":"PureIMS","sponsor":"Boost-UP Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PureIMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Dry Powder","sponsorNew":"PureIMS \/ Boost-UP Foundation","highestDevelopmentStatusID":"10","companyTruncated":"PureIMS \/ Boost-UP Foundation"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":2.6000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":2.6000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":2.6000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":2.6000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"GV1001","moa":"peptides","graph1":"Neurology","graph2":"Phase III","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Nanjing NingQi Medicine Science and Technology Co., Ltd.","sponsor":"Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | The First Affiliated Hospital with Nanjing Medical University | Jiangsu Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Huangqi Guizhi Wuwu","moa":"Unknown","graph1":"Neurology","graph2":"Phase III","graph3":"Nanjing NingQi Medicine Science and Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanjing NingQi Medicine Science and Technology Co., Ltd. \/ Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | The First Affiliated Hospital with Nanjing Medical University | Jiangsu Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Nanjing NingQi Medicine Science and Technology Co., Ltd. \/ Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | The First Affiliated Hospital with Nanjing Medical University | Jiangsu Cancer Institute"},{"orgOrder":0,"company":"Harley Street (CPC) Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Cannabis","moa":"Cannabinoid receptor 1; Cannabinoid receptor 2; G-protein coupled receptor 12; Glycine receptor subunit alpha-1; Glycine receptor (alpha-1\/beta); Glycine receptor subunit alpha-3; N-arachidonyl glycine receptor; G-protein coupled receptor 55; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A; Neuronal acetylcholine receptor subunit alpha-7; Delta-type opioid receptor; Mu-type opioid receptor; Peroxisome proliferator-activated receptor gamma; Transient receptor potential cation channel subfamily V member 1; Voltage-dependent T-type calcium channel subunit alpha-1G; Voltage-dependent T-type calcium channel subunit alpha-1H; Voltage-dependent T-type calcium channel subunit alpha-1I; Transient receptor potential cation channel subfamily A member 1; Transient receptor potential cation channel subfamily M member 8; Transient receptor potential cation channel subfamily V member 2; Transient receptor potential cation channel subfamily V member 3; Transient receptor potential cat","graph1":"Neurology","graph2":"Phase III","graph3":"Harley Street (CPC) Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Harley Street (CPC) Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harley Street (CPC) Limited \/ Inapplicable"},{"orgOrder":0,"company":"WALA Heilmittel GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Aconite","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"WALA Heilmittel GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Oil","sponsorNew":"WALA Heilmittel GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"WALA Heilmittel GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Jishengtang Pharmaceutical Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Wujia Yizhi","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Sichuan Jishengtang Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Sichuan Jishengtang Pharmaceutical Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sichuan Jishengtang Pharmaceutical Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Orlando Health","sponsor":"CHIRHOCLIN","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Human Secretin","moa":"Secretin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Orlando Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orlando Health \/ CHIRHOCLIN","highestDevelopmentStatusID":"10","companyTruncated":"Orlando Health \/ CHIRHOCLIN"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Immune Globulin (Human)","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Neurology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Innopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Innopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innopharm \/ Inapplicable"},{"orgOrder":0,"company":"Zionexa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SPECT","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Zionexa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zionexa \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zionexa \/ Inapplicable"},{"orgOrder":0,"company":"Vivozon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VVZ-149","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vivozon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vivozon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vivozon \/ Inapplicable"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Tolperisone","moa":"deuterated compounds","graph1":"Neurology","graph2":"Phase III","graph3":"Neurana Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurana Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurana Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corestemchemon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lenzumestrocel","moa":"Autologous mesenchymal stem cells","graph1":"Neurology","graph2":"Phase III","graph3":"Corestemchemon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Corestemchemon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corestemchemon \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR8554","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Medlab Clinical","sponsor":"George Clinical | WriteSource Medical Pty Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Delta 9 Tetrahydrocannabinol","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Medlab Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medlab Clinical \/ George Clinical | WriteSource Medical Pty Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Medlab Clinical \/ George Clinical | WriteSource Medical Pty Ltd"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR0410","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TAK-771","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Julius Clinical | TRICALS Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"FAB122","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Julius Clinical | TRICALS Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Julius Clinical | TRICALS Foundation"},{"orgOrder":0,"company":"Assaf-Harofeh Medical Center","sponsor":"Seach Sarid Ltd | Canndoc Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Cannabis Oil","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Assaf-Harofeh Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Assaf-Harofeh Medical Center \/ Seach Sarid Ltd | Canndoc Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Assaf-Harofeh Medical Center \/ Seach Sarid Ltd | Canndoc Ltd"},{"orgOrder":0,"company":"Apothyx, Co.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Goodfor Pain","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Apothyx, Co.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apothyx, Co. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apothyx, Co. \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR0410","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pharmbio Korea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PBK_L1704","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Pharmbio Korea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmbio Korea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmbio Korea \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MT-1186","moa":"TDP-43","graph1":"Neurology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vertanical GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VER-01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Vertanical GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vertanical GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertanical GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Ecopipam HCl","moa":"DRD1","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Vivozon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VVZ-149","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vivozon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vivozon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vivozon \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HR18034","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FAB122","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Inapplicable"},{"orgOrder":0,"company":"CereMark Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Radiolabeled Compounds","year":"2024","type":"Inapplicable","leadProduct":"18-F Flornaptitril","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"CereMark Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CereMark Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CereMark Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HCP1004","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABP 692","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TAK-881","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"YZJ-4729 Tartrate","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Bemadaprost","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueRock Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"BlueRock Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Vertanical GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VER-01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Vertanical GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vertanical GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertanical GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"National Aeronautics and Space Administration","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ National Aeronautics and Space Administration","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ National Aeronautics and Space Administration"},{"orgOrder":0,"company":"PainReform","sponsor":"Lotus Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"PainReform","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution, Extended Release","sponsorNew":"PainReform \/ Lotus Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"PainReform \/ Lotus Clinical Research"},{"orgOrder":0,"company":"Criceto Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Criceto Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Criceto Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Criceto Pharmaceuticals \/ Orion Corporation"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BK1301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Repurposed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DPI-386","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Repurposed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Repurposed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Repurposed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin-gene-related peptide receptor, CALCRL\/RAMP1","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin-gene-related peptide receptor, CALCRL\/RAMP1","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Zavegepant HCl","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.45000000000000001,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR8554","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR8554","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lu AF82422","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase III","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPN-817","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PureIMS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PureIMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Dry Powder","sponsorNew":"PureIMS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PureIMS \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase III","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase III","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase III","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase III","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HR18034","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR0410","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR8554","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Vertanical GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VER-01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Vertanical GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Vertanical GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertanical GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HR18034","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"YZJ-4729 Tartrate","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"YZJ-4729 Tartrate","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"PainReform","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"PainReform","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution, Extended Release","sponsorNew":"PainReform \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PainReform \/ Inapplicable"},{"orgOrder":0,"company":"PainReform","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"PainReform","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Topical Solution, Extended Release","sponsorNew":"PainReform \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"PainReform \/ Maxim Group LLC"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cerecin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tricaprylin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Cerecin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerecin \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerecin \/ Inapplicable"},{"orgOrder":0,"company":"Unither Pharmaceuticals","sponsor":"Raptim Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Unither Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Solution","sponsorNew":"Unither Pharmaceuticals \/ Raptim Research","highestDevelopmentStatusID":"10","companyTruncated":"Unither Pharmaceuticals \/ Raptim Research"},{"orgOrder":0,"company":"Cerecin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tricaprylin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Cerecin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerecin \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerecin \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HSK3486","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Cerecin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tricaprylin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Cerecin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerecin \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerecin \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Solengepras","moa":"G-protein coupled receptor 6 (GPR6)","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HSK3486","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MT-1186","moa":"TDP-43","graph1":"Neurology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"18-F Flortaucipir","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"18-F Flortaucipir","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"M207","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Corestemchemon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Lenzumestrocel","moa":"Autologous mesenchymal stem cells","graph1":"Neurology","graph2":"Phase III","graph3":"Corestemchemon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Corestemchemon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corestemchemon \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase III","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase III","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor; anion channel | Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SK Life Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SK Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase III","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clene Nanomedicine \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"ScandiBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"ScandiBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ScandiBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ScandiBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sinotau Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"XTR006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Sinotau Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinotau Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinotau Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin-gene-related peptide receptor, CALCRL\/RAMP1","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"IncobotulinumtoxinA","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"IncobotulinumtoxinA","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"RUSSIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Divozilimab","moa":"CD20","graph1":"Neurology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HRG2010","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPN-817","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Central Hospital, Nancy, France","sponsor":"Farco-Pharma GmbH | Ministry of Health, France","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Oxybutynin Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Central Hospital, Nancy, France","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Central Hospital, Nancy, France \/ Farco-Pharma GmbH | Ministry of Health, France","highestDevelopmentStatusID":"10","companyTruncated":"Central Hospital, Nancy, France \/ Farco-Pharma GmbH | Ministry of Health, France"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Empasiprubart","moa":"C2","graph1":"Neurology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Relutrigine","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ACP-204","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ACP-204","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Rovatirelin","moa":"Thyrotropin-releasing hormone receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GM1","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haukeland University Hospital","sponsor":"Niagen Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NORWAY","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Phase III","graph3":"Haukeland University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Haukeland University Hospital \/ Niagen Bioscience","highestDevelopmentStatusID":"10","companyTruncated":"Haukeland University Hospital \/ Niagen Bioscience"}]
Find Neurology Drugs in Phase III Clinical Development
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target